Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Nasdaq4d
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...